Association of ACEI/ARB and statin prescribing patterns with mortality after Transcatheter Aortic Valve Replacement (TAVR) : Findings from real-world claims data
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become the standard of care for most patients with severe aortic stenosis (AS), but the impact of medical therapy prescribing patterns on post-TAVR patients has not been thoroughly investigated.
METHODS: We analyzed Optum claims data from 9,012 adults who received TAVR for AS (January 2014-December 2018). Pharmacy claims data were used to identify patients who filled ACEI/ARB and/or statin prescriptions during the study's 90-day landmark period post-TAVR. Kaplan-Meier and adjusted Cox Proportional Hazards models were used to evaluate the association of prescribing patterns with mortality during the 3-year follow-up period. Subgroup analyses were performed to examine the impact of 11 potential confounders on the observed associations.
RESULTS: A significantly lower adjusted 3-year mortality was observed for patients with post-TAVR prescription for ACEI/ARBs (hazard ratio [HR] = 0.82, 95% confidence interval [CI] 0.74-0.91, P = .0003) and statins (HR = 0.85, 95% CI 0.77-0.94, P = .0018) compared to patients who did not fill prescriptions for these medications post-TAVR. Subgroup analyses revealed that the survival benefit associated with ACEI/ARB prescription was not affected by any of the potential confounding variables, except preoperative ACEI/ARB prescription was associated with significantly lower risk of mortality vs postoperative prescription only. No other subgroup variables had significant interactions associated with survival benefits, including preoperative use of statins.
CONCLUSIONS: In this large-scale, real-world analysis of patients undergoing TAVR, the prescription of ACEI/ARB and statins was associated with a significantly lower risk of mortality at 3-years, especially in those where the medications were initiated preoperatively.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:258 |
|---|---|
| Enthalten in: |
American heart journal - 258(2023) vom: 05. Apr., Seite 27-37 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cubeddu, Robert J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 09.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ahj.2022.12.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351075518 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351075518 | ||
| 003 | DE-627 | ||
| 005 | 20231226050449.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ahj.2022.12.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351075518 | ||
| 035 | |a (NLM)36596333 | ||
| 035 | |a (PII)S0002-8703(22)00333-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cubeddu, Robert J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of ACEI/ARB and statin prescribing patterns with mortality after Transcatheter Aortic Valve Replacement (TAVR) |b Findings from real-world claims data |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 09.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become the standard of care for most patients with severe aortic stenosis (AS), but the impact of medical therapy prescribing patterns on post-TAVR patients has not been thoroughly investigated | ||
| 520 | |a METHODS: We analyzed Optum claims data from 9,012 adults who received TAVR for AS (January 2014-December 2018). Pharmacy claims data were used to identify patients who filled ACEI/ARB and/or statin prescriptions during the study's 90-day landmark period post-TAVR. Kaplan-Meier and adjusted Cox Proportional Hazards models were used to evaluate the association of prescribing patterns with mortality during the 3-year follow-up period. Subgroup analyses were performed to examine the impact of 11 potential confounders on the observed associations | ||
| 520 | |a RESULTS: A significantly lower adjusted 3-year mortality was observed for patients with post-TAVR prescription for ACEI/ARBs (hazard ratio [HR] = 0.82, 95% confidence interval [CI] 0.74-0.91, P = .0003) and statins (HR = 0.85, 95% CI 0.77-0.94, P = .0018) compared to patients who did not fill prescriptions for these medications post-TAVR. Subgroup analyses revealed that the survival benefit associated with ACEI/ARB prescription was not affected by any of the potential confounding variables, except preoperative ACEI/ARB prescription was associated with significantly lower risk of mortality vs postoperative prescription only. No other subgroup variables had significant interactions associated with survival benefits, including preoperative use of statins | ||
| 520 | |a CONCLUSIONS: In this large-scale, real-world analysis of patients undergoing TAVR, the prescription of ACEI/ARB and statins was associated with a significantly lower risk of mortality at 3-years, especially in those where the medications were initiated preoperatively | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ACEI/ARB | |
| 650 | 4 | |a Aortic stenosis | |
| 650 | 4 | |a Renin-angiotensin system inhibitor | |
| 650 | 4 | |a Statin | |
| 650 | 4 | |a Transcatheter aortic valve replacement | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 700 | 1 | |a Murphy, Shannon M E |e verfasserin |4 aut | |
| 700 | 1 | |a Asher, Craig R |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Santiago A |e verfasserin |4 aut | |
| 700 | 1 | |a Granada, Juan F |e verfasserin |4 aut | |
| 700 | 1 | |a Don, Creighton W |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Sankalp |e verfasserin |4 aut | |
| 700 | 1 | |a Albaghdadi, Mazen S |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalcante, João L |e verfasserin |4 aut | |
| 700 | 1 | |a Coylewright, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Hahn, Rebecca T |e verfasserin |4 aut | |
| 700 | 1 | |a Genereux, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Pradeep K |e verfasserin |4 aut | |
| 700 | 1 | |a Thourani, Vinod H |e verfasserin |4 aut | |
| 700 | 1 | |a Leon, Martin B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American heart journal |d 1945 |g 258(2023) vom: 05. Apr., Seite 27-37 |w (DE-627)NLM000012270 |x 1097-6744 |7 nnns |
| 773 | 1 | 8 | |g volume:258 |g year:2023 |g day:05 |g month:04 |g pages:27-37 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ahj.2022.12.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 258 |j 2023 |b 05 |c 04 |h 27-37 | ||